Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Verona Pharma (VRNA – Research Report), boosting the price target to ...

H.C. Wainwright raised the firm’s price target on Verona Pharma (VRNA) to $42 from $36 and keeps a Buy rating on the shares post the Q3 ...

Q3 2024 Earnings Call Transcript November 4, 2024 Verona Pharma plc beats earnings expectations. Reported EPS is $-0.08819, ...

Verona Pharma (Nasdaq: VRNA) is already recording millions of dollars in revenue after launching its lead drug in August ...

Verona Pharma PLC (VRNA) reports significant sales growth for Ohtuvayre, but faces increased expenses and competition in the COPD market.

Q3 2024 Earnings Conference Call November 4, 2024 9:00 AM ETCompany ParticipantsDavid Zaccardelli - President and ...

Highlights:,Ohtuvayre™ generates $5.6 million in net sales in its first seven weeks, signaling a strong market entry.,October ...

Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3 Through October more ...

At the heart of Verona Pharma’s recent success is Ohtuvayre (ensifentrine), a revolutionary treatment for chronic obstructive pulmonary disease (COPD). According to David Zaccardelli, the President ...

Verona Pharma (NASDAQ:VRNA) is scheduled to announce Q3 earnings results on Monday, November 4th, before market open. The consensus EPS Estimate is -$0.41 and the consensus Revenue Estimate is $2.01M.

Wells Fargo has set a $50 target on Verona Pharma, suggesting the potential of Ohtuvayre, a treatment for Chronic Obstructive Pulmonary Disease (COPD), could exceed market expectations.

NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Questex's Fierce Healthcare, Fierce Biotech and Fierce Pharma today announce the finalists of the Fierce Healthcare Innovation Awards and the Fierce Life ...